DENVER, July 16, 2009 (GLOBE NEWSWIRE) -- The law firm of Dyer & Berens LLP (www.DyerBerens.com) announced today that it has initiated an investigation concerning losses suffered by certain Caraco Pharmaceutical Laboratories Ltd. investors (AMEX:CPD).
The investigation focuses on whether Caraco, the maker of generic pharmaceuticals, made false or misleading statements or failed to disclose that the company's manufacturing processes were not compliant with the FDA's Good Manufacturing Practice requirements. This investigation was prompted by news reports on June 25, 2009 stating that U.S. Marshals recently seized drug products manufactured by Caraco from the company's facilities. In response to this disclosure, shares of Caraco stock plummeted from $4.15 per share to as low as $1.75 per share on June 25, 2009.
If you have information relevant to the investigation, or if you believe you were harmed by the conduct described above, you may contact Jeffrey A. Berens, Esq. at 1-888-300-3362 or via email at jeff@dyerberens.com.
The law firm of Dyer & Berens LLP focuses on complex class action litigation on behalf of injured investors throughout the nation. The firm's extensive experience in securities litigation, particularly in cases brought under the Private Securities Litigation Reform Act, has contributed to the recovery of hundreds of millions of dollars for aggrieved investors. For more information about the firm, please go to www.DyerBerens.com.